Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer: A systematic review

Research output: Contribution to journalReviewResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Rasmussen, Christina L ; Bertoli, Hanna K ; Sand, Freja L ; Kjaer, Alexander K ; Thomsen, Louise T ; Kjaer, Susanne K. / The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer : A systematic review. In: Acta Obstetricia et Gynecologica Scandinavica. 2021 ; Vol. 100, No. 12. pp. 2144-2156.

Bibtex

@article{94774d4195d848c1a7e07673d01646e1,
title = "The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer: A systematic review",
abstract = "INTRODUCTION: Human papillomavirus (HPV), p16, and p53 have been investigated as prognostic markers in various HPV-related cancers. Within the field of vaginal cancer, however, the evidence remains sparse. In this systematic review, we have compiled the presently published studies on the prognostic significance of HPV and immunohistochemical expression of p16 and p53 among women with vaginal cancer.MATERIAL AND METHODS: We conducted a systematic search of PubMed, Embase, and Cochrane Library to identify relevant studies published until April 2021. We included studies reporting survival after histologically verified vaginal cancers tested for HPV, p16, and/or p53. Survival outcomes included overall survival, disease-free survival, disease-specific survival, and progression-free survival.RESULTS: We included a total of 12 studies. The vast majority of vaginal cancer cases included in each study were squamous cell carcinomas (84%-100%). Seven studies reported survival after vaginal cancer according to HPV status, and the majority of these studies found a tendency towards improved survival for women with HPV-positive vaginal cancer. Three out of four studies reporting survival according to p16 status found an improved survival among women with p16-positive vaginal cancer. For p53, only one of six studies reported an association between p53 expression and survival.CONCLUSIONS: This systematic review suggests that women with HPV- and p16-positive vaginal cancer have an improved prognosis compared with those with HPV- or p16-negative vaginal cancer. Results for p53 were varied, and no conclusion could be reached. Only 12 studies could be included in the review, of which most were based on small populations. Hence, further and larger studies on the prognostic impact of HPV, p16, and p53 in vaginal cancer are warranted.",
keywords = "Alphapapillomavirus/isolation & purification, Carcinoma, Squamous Cell/metabolism, Cyclin-Dependent Kinase Inhibitor p16/metabolism, Disease-Free Survival, Female, Humans, Prognosis, Tumor Suppressor Protein p53/metabolism, Vaginal Neoplasms/metabolism, survival, prognosis, p53, vaginal cancer, p16, human papillomavirus",
author = "Rasmussen, {Christina L} and Bertoli, {Hanna K} and Sand, {Freja L} and Kjaer, {Alexander K} and Thomsen, {Louise T} and Kjaer, {Susanne K}",
note = "{\textcopyright} 2021 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).",
year = "2021",
month = dec,
doi = "10.1111/aogs.14260",
language = "English",
volume = "100",
pages = "2144--2156",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "Informa Healthcare",
number = "12",

}

RIS

TY - JOUR

T1 - The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer

T2 - A systematic review

AU - Rasmussen, Christina L

AU - Bertoli, Hanna K

AU - Sand, Freja L

AU - Kjaer, Alexander K

AU - Thomsen, Louise T

AU - Kjaer, Susanne K

N1 - © 2021 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).

PY - 2021/12

Y1 - 2021/12

N2 - INTRODUCTION: Human papillomavirus (HPV), p16, and p53 have been investigated as prognostic markers in various HPV-related cancers. Within the field of vaginal cancer, however, the evidence remains sparse. In this systematic review, we have compiled the presently published studies on the prognostic significance of HPV and immunohistochemical expression of p16 and p53 among women with vaginal cancer.MATERIAL AND METHODS: We conducted a systematic search of PubMed, Embase, and Cochrane Library to identify relevant studies published until April 2021. We included studies reporting survival after histologically verified vaginal cancers tested for HPV, p16, and/or p53. Survival outcomes included overall survival, disease-free survival, disease-specific survival, and progression-free survival.RESULTS: We included a total of 12 studies. The vast majority of vaginal cancer cases included in each study were squamous cell carcinomas (84%-100%). Seven studies reported survival after vaginal cancer according to HPV status, and the majority of these studies found a tendency towards improved survival for women with HPV-positive vaginal cancer. Three out of four studies reporting survival according to p16 status found an improved survival among women with p16-positive vaginal cancer. For p53, only one of six studies reported an association between p53 expression and survival.CONCLUSIONS: This systematic review suggests that women with HPV- and p16-positive vaginal cancer have an improved prognosis compared with those with HPV- or p16-negative vaginal cancer. Results for p53 were varied, and no conclusion could be reached. Only 12 studies could be included in the review, of which most were based on small populations. Hence, further and larger studies on the prognostic impact of HPV, p16, and p53 in vaginal cancer are warranted.

AB - INTRODUCTION: Human papillomavirus (HPV), p16, and p53 have been investigated as prognostic markers in various HPV-related cancers. Within the field of vaginal cancer, however, the evidence remains sparse. In this systematic review, we have compiled the presently published studies on the prognostic significance of HPV and immunohistochemical expression of p16 and p53 among women with vaginal cancer.MATERIAL AND METHODS: We conducted a systematic search of PubMed, Embase, and Cochrane Library to identify relevant studies published until April 2021. We included studies reporting survival after histologically verified vaginal cancers tested for HPV, p16, and/or p53. Survival outcomes included overall survival, disease-free survival, disease-specific survival, and progression-free survival.RESULTS: We included a total of 12 studies. The vast majority of vaginal cancer cases included in each study were squamous cell carcinomas (84%-100%). Seven studies reported survival after vaginal cancer according to HPV status, and the majority of these studies found a tendency towards improved survival for women with HPV-positive vaginal cancer. Three out of four studies reporting survival according to p16 status found an improved survival among women with p16-positive vaginal cancer. For p53, only one of six studies reported an association between p53 expression and survival.CONCLUSIONS: This systematic review suggests that women with HPV- and p16-positive vaginal cancer have an improved prognosis compared with those with HPV- or p16-negative vaginal cancer. Results for p53 were varied, and no conclusion could be reached. Only 12 studies could be included in the review, of which most were based on small populations. Hence, further and larger studies on the prognostic impact of HPV, p16, and p53 in vaginal cancer are warranted.

KW - Alphapapillomavirus/isolation & purification

KW - Carcinoma, Squamous Cell/metabolism

KW - Cyclin-Dependent Kinase Inhibitor p16/metabolism

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Prognosis

KW - Tumor Suppressor Protein p53/metabolism

KW - Vaginal Neoplasms/metabolism

KW - survival

KW - prognosis

KW - p53

KW - vaginal cancer

KW - p16

KW - human papillomavirus

UR - http://www.scopus.com/inward/record.url?scp=85115271733&partnerID=8YFLogxK

U2 - 10.1111/aogs.14260

DO - 10.1111/aogs.14260

M3 - Review

C2 - 34546565

VL - 100

SP - 2144

EP - 2156

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 12

ER -

ID: 73986769